United Therapeutics Corp (UTHR) CEO’s trust sells 9,500 shares under 10b5-1 plan
Rhea-AI Filing Summary
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 and acquired an equal number of common shares on 2026-08-12. The trust then sold 9,500 common shares in multiple trades at weighted-average prices around $507–$521 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. After the option exercise, the family trust held 151,410 stock options with a March 15, 2027 expiration, while Rothblatt also reported 40,513 directly held common shares and 166 shares held indirectly by a spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.61M approx. pre-tax spread)
Exercise and Sale
21 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($4.89M)
Approx. gross sale proceeds
$4.89M
Approx. exercise cost
$1.29M
Approx. pre-tax spread
$3.61M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F20 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock F1, F3, F2 | 40 | $507.076 | $20K |
| Sale | Common Stock F1, F4, F2 | 440 | $508.8598 | $224K |
| Sale | Common Stock F1, F5, F2 | 280 | $509.6114 | $143K |
| Sale | Common Stock F1, F6, F2 | 1,152 | $511.1178 | $589K |
| Sale | Common Stock F1, F7, F2 | 542 | $511.7471 | $277K |
| Sale | Common Stock F1, F8, F2 | 1,206 | $513.0168 | $619K |
| Sale | Common Stock F1, F9, F2 | 558 | $514.1839 | $287K |
| Sale | Common Stock F1, F10, F2 | 893 | $514.8746 | $460K |
| Sale | Common Stock F1, F11, F2 | 940 | $516.1606 | $485K |
| Sale | Common Stock F1, F12, F2 | 1,249 | $517.2146 | $646K |
| Sale | Common Stock F1, F13, F2 | 320 | $518.1566 | $166K |
| Sale | Common Stock F1, F14, F2 | 1,160 | $519.4888 | $603K |
| Sale | Common Stock F1, F15, F2 | 679 | $520.3779 | $353K |
| Sale | Common Stock F1, F16, F2 | 41 | $520.9598 | $21K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F17 | -- | -- | -- |
| holding | Common Stock F18 | -- | -- | -- |
| holding | Common Stock F19 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 151,410 shares (Indirect, by Trust);
Common Stock — 628,049 shares (Indirect, by Trust);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (20)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $514.63 to $515.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $515.63 to $516.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $516.63 to $517.625. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. This transaction was executed in multiple trades at prices ranging from $517.66 to $518.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F14. This transaction was executed in multiple trades at prices ranging from $518.92 to $519.885. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F15. This transaction was executed in multiple trades at prices ranging from $519.92 to $520.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F16. This transaction was executed in multiple trades at prices ranging from $520.95 to $520.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F17. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F18. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F19. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F20. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $506.59 to $507.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $508.24 to $509.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $509.39 to $510.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $510.45 to $511.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $511.46 to $512.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $512.46 to $513.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $513.55 to $514.525. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 9,500 shares
Exercise price: $135.42 per share
Shares sold: 9,500 shares
+5 more
8 metrics
Options exercised
9,500 shares
Stock options exercised by family trust on 2026-08-12
Exercise price
$135.42 per share
Exercise price of stock options converted into common stock
Shares sold
9,500 shares
Common shares sold in multiple trades on 2026-08-12
Sale price range (weighted averages)
$507.08–$520.96 per share
Weighted-average prices reported across sale tranches
Options held after exercise
151,410 options
Stock options held by family trust after 9,500-share exercise
Direct common shares
40,513 shares
Common stock directly held by Martine A. Rothblatt
Spouse-held shares
166 shares
Common stock indirectly held by spouse
Plan option capacity
1,734,410 options
Maximum stock options covered by Rule 10b5-1 plan
Key Terms
Rule 10b5-1 trading plan, weighted average price, indirect ownership, family trusts, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirect ownership financial
"ownership_type indirect and nature_of_ownership by Trust"
family trusts financial
"Shares held in family trusts as to which the Reporting Person’s spouse"
exercise or conversion of derivative security financial
"transaction_code_description Exercise or conversion of derivative security"
FAQ
What insider transactions did UTHR CEO Martine Rothblatt report on August 12, 2026?
Rothblatt’s family trust exercised 9,500 stock options at $135.42 and sold 9,500 common shares in multiple trades at weighted-average prices around $507–$521 per share, all reported on the Form 4 for United Therapeutics (UTHR).
Were the August 2026 UTHR insider trades by Martine Rothblatt under a Rule 10b5-1 plan?
Yes. The Form 4 states the option exercise and related share sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which runs until certain option exercises are completed or December 31, 2026.
What stock options did UTHR’s CEO exercise in the latest Form 4 filing?
A family trust associated with the CEO exercised 9,500 stock options with an exercise price of $135.42 per share, converting them into an equal number of United Therapeutics common shares. These options expire on March 15, 2027, according to the filing details.
What is the size of the 10b5-1 option plan referenced in the UTHR Form 4?
The Rule 10b5-1 plan covers the potential exercise of up to 1,734,410 stock options, all expiring on March 15, 2027, or runs until December 31, 2026, whichever comes first, according to the Form 4 footnote for United Therapeutics’ CEO.
AI-generated analysis. How Rhea-AI works. Not financial advice.